|
| Press Releases |
|
 |
|
| Tuesday, February 5, 2013 |
|
|
亨得利回購股份 前景樂觀 |
亨得利 (3389-HK) 近期頻頻大手回購股份，表示公司對未來發展之信心，業務及盈利前景仍然樂觀。
more info >> |
|
| Friday, February 1, 2013 |
|
|
亨得利斥资1,351万港元回购500万股 增强股东信心 |
亨得利 (3389-HK) 于2013年1月31日公布，公司在香港交易所回购500万股股份，每股回购价介乎2.69港元至2.72港元，涉及资金约1,351万港元。
more info >> |
|
|
亨得利斥資1,351萬港元回購500萬股 增強股東信心 |
亨得利 (3389-HK) 於2013年1月31日公佈，公司在香港交易所回購500萬股股份，每股回購價介乎2.69港元至2.72港元，涉及資金約1,351萬港元。
more info >> |
|
|
Hengdeli Repurchases 5 Million Shares, Strengthening Shareholders' Confidence with Confidence in Business Outlook |
Hengdeli (3389-HK) announced that the Company repurchased a total of 5 million of its shares on the Hong Kong Stock Exchange on 31 January 2013, with the price per share between HK$2.69 and HK$2.72, involved capital amounted to approximately HK$13.51 million.
more info >> |
|
| Thursday, January 31, 2013 |
|
|
亨得利：零售网络发展健康 |
就昨日传媒质疑亨得利 (3389) 的营运模式，公司公告指出，一切业务皆在正常运作及健康平稳发展。
more info >> |
|
|
亨得利：零售網絡發展健康 |
就昨日傳媒質疑亨得利 (3389) 的營運模式，公司公告指出，一切業務皆在正常運作及健康平穩發展。
more info >> |
|
|
亨得利表示公司稳健 |
对于昨日有报导对亨得利(3389) 的经营及财务状况有负面揣测及质疑，该公司昨晚发出公告交代公司近况，指其审慎进取的发展原则一直没有改变，而最近几年间亦取得经营业绩的稳定增长。其主要股东Swatch行政总裁Nick Hayek昨日接受访问时表示，对亨得利非常满意，合作一切进展顺利，合作关系没有改变。
more info >> |
|
|
亨得利表示公司穩健 |
對於昨日有報導對亨得利(3389) 的經營及財務狀況有负面揣测及質疑，該公司昨晚發出公告交代公司近况，指其審慎進取的發展原則一直沒有改變，而最近幾年間亦取得經營業績的穩定增長。其主要股東Swatch行政總裁Nick Hayek昨日接受訪問時表示，對亨得利非常滿意，合作一切進展順利，合作關係沒有改變。
more info >> |
|
| Monday, October 15, 2012 |
|
|
Watch Seller Hengdeli Posts Double-digit Sales Growth in Golden Week and Third-quarter |
Hengdeli Holdings Ltd. <3389.HK>, a luxurious watch retailer in the Greater China, said sales registered double-digit growth in total during the Golden Week holiday and third-quarter.
more info >> |
|
| Wednesday, June 6, 2012 |
|
|
Hengdeli Says Mid-range Watch Market Looks Promising |
| Zhang Yuping, chairman of Hengdeli, which has an over 30% share of China's high-end watch market, said the company expects to see a "low double-digit growth" in same-store sales this year, a significant drop compared with the 36% increase for 2011. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施
Feb 25, 2026 18:07 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 17:29 HKT/SGT
|
|
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 14:58 HKT/SGT
|
|
|
Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎來國際長線接盤 機器人產業生態進入價值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
|
|
|
康哲藥業（867.HK/8A8.SG）：創新藥磷酸蘆可替尼乳膏增加特應性皮炎（AD）適應症中國上市許可申請獲受理並獲納入優先審評
Feb 24, 2026 20:31 HKT/SGT
|
|
|
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评
Feb 24, 2026 20:19 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
